Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

NCT05577182 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Incyte Corporation